[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Lyme Disease (Infectious Disease) - Drugs in Development, 2021

March 2021 | 67 pages | ID: L300944B04F1EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Lyme Disease (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lyme Disease - Drugs in Development, 2021, provides an overview of the Lyme Disease (Infectious Disease) pipeline landscape.

Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches and headache. Risk factors include age, gender and geographic locations. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lyme Disease - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Lyme Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lyme Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Lyme Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lyme Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lyme Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lyme Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lyme Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lyme Disease (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lyme Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lyme Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Lyme Disease - Overview
Lyme Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Lyme Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lyme Disease - Companies Involved in Therapeutics Development
Abzyme Therapeutics LLC
Agile Sciences Inc
Artes Biotechnology GmbH
Cortene Inc
Flightpath BioSciences Inc
Greffex Inc
Inovio Pharmaceuticals Inc
Ixodes AG
L2 Diagnostics LLC
NovoBiotic Pharmaceuticals LLC
Reven Pharmaceuticals Inc
Valneva SE
Lyme Disease - Drug Profiles
azithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azlocillin sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bi-specific Monoclonal Antibody to Inhibit CRASP1 for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desloratadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
disulfiram - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit OspA for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hygromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyme disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPOT-1003a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLA-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyme Disease - Dormant Projects
Lyme Disease - Product Development Milestones
Featured News & Press Releases
Mar 08, 2021: Valneva and Pfizer announce initiation of phase 2 study for Lyme disease vaccine candidate
Dec 02, 2020: Valneva announces acceleration of pediatric development for lyme disease vaccine candidate
Oct 20, 2020: Valneva announces positive initial results for second phase 2 study of Lyme disease vaccine candidate VLA15
Jul 22, 2020: Valneva announces positive initial results for phase 2 study of Lyme disease vaccine candidate
Sep 30, 2019: Valneva completes recruitment for phase 2 studies of its Lyme Disease vaccine candidate VLA15
Jul 03, 2019: Valneva: Renowned Vaccinologist Dr. Stanley Plotkin to Present on VLA-15 at R&D Investor Day in New York City
Jul 01, 2019: Valneva initiates second phase 2 study for its Lyme Disease Vaccine Candidate VLA15
Jun 12, 2019: Valneva reports successful outcome of phase 2 run-in for its lyme disease vaccine candidate
Jun 11, 2019: Valneva to present Lyme Disease vaccine update at R&D Investor Day in New York City on July 9th
Apr 09, 2019: Valneva to present on Lyme vaccine candidate at the 19th World Vaccine Congress
Jan 31, 2019: VALNEVA reports positive initial booster data and final phase 1 data for its lyme disease vaccine candidate
Dec 17, 2018: Valneva starts Phase ll trial of VLA15 to treat Lyme disease
Oct 25, 2018: VALNEVA receives positive feedback from EMA on its further development for lyme disease vaccine VLA15
Jul 02, 2018: Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate
Mar 29, 2018: VALNEVA to Present on Lyme disease candidate VLA-15 at the 18th World Vaccine Congress in Washington, D.C.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Lyme Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Lyme Disease - Pipeline by Abzyme Therapeutics LLC, 2021
Lyme Disease - Pipeline by Agile Sciences Inc, 2021
Lyme Disease - Pipeline by Artes Biotechnology GmbH, 2021
Lyme Disease - Pipeline by Cortene Inc, 2021
Lyme Disease - Pipeline by Flightpath BioSciences Inc, 2021
Lyme Disease - Pipeline by Greffex Inc, 2021
Lyme Disease - Pipeline by Inovio Pharmaceuticals Inc, 2021
Lyme Disease - Pipeline by Ixodes AG, 2021
Lyme Disease - Pipeline by L2 Diagnostics LLC, 2021
Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals LLC, 2021
Lyme Disease - Pipeline by Reven Pharmaceuticals Inc, 2021
Lyme Disease - Pipeline by Valneva SE, 2021
Lyme Disease - Dormant Projects, 2021

LIST OF FIGURES

Number of Products under Development for Lyme Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


More Publications